Avantis Medical Systems Receives 510(k) Clearance from FDA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Avantis Medical Systems Receives 510(k) Clearance from FDA for Resposable Third Eye® Panoramic™ Device for Colonoscopy

SAN JOSE, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Avantis Medical Systems, Inc., a technology leader in developing novel digital imaging devices, today announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its Third Eye® Panoramic™ device for use as a resposable product for colonoscopies.  Previously cleared as a disposable device, this latest clearance now allows Third Eye Panoramic to be marketed in the U.S. as a resposable device that can be used multiple times prior to disposal. Photos accompanying this release are available at

http://www.globenewswire.com/NewsRoom/Attachm...c96826c33f

http://www.globenewswire.com/NewsRoom/Attachm...4a8e7a3c64

Third Eye Panoramic is a wide-view visualization device designed to provide gastroenterologists (GIs) and other endoscopists a better look at areas of the colon where cancers and pre-cancerous polyps may be hidden from the view of a traditional colonoscope alone, such as behind folds.  This is the only optical device on the market that can easily be used in conjunction with any commonly used colonoscope to improve visualization.  Physicians can integrate the Third Eye Panoramic within their current practices without the need to invest in expensive infrastructure.

“This clearance represents a significant milestone for our organization, as we can now offer the resposable Third Eye Panoramic device to the medical community in the U.S.,” said Anthony DiTonno, CEO of Avantis Medical Systems.  “The resposable version of our device provides the same ultra-wide-angle view of the colon as the disposable predicate device, with a much lower cost per procedure. Physicians and facilities will benefit from this innovative technology from both clinical and financial perspectives, and the ultimate winners will be their patients.”

The Third Eye Panoramic device contains two video cameras that are directed laterally from its left and right sides.  The device is attached to the tip of the colonoscope at the beginning of the procedure, and can be used during both the insertion and withdrawal phases.  The Third Eye Panoramic’s lateral images are displayed on each side of the colonoscope’s forward image, resulting in an ultra-wide-angle view of more than 300 degrees.  This “panoramic” view reveals areas behind folds and flexures (sharp turns) in the colon.

Based on clinical experience, physicians reported that when using the Third Eye Panoramic they were able to detect pre-cancerous polyps called adenomas in 44% of patients. 1

“I have used the Third Eye Panoramic in dozens of procedures as part of a feasibility study, and I found that the device is easy to use and doesn’t interfere with the function of the colonoscope,” said Moshe Rubin, MD, Director of Gastroenterology, New York-Presbyterian/Queens – Weill Cornell Medical College.  “This device accomplishes the goal of expanding the view without requiring conversion to a new scope platform or sacrificing the high-definition image quality and superior handling characteristics of standard colonoscopes.”

The cleaning and disinfection protocols for this device are similar to the methods used to reprocess colonoscopes between uses.

Following this FDA clearance, the company now plans to launch the product as a multi-use device and is currently evaluating strategic partnerships to drive commercial availability.

About Colorectal Cancer

Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths in the United States. According to the American Cancer Society, about 150,000 people in the U.S. are diagnosed with CRC each year and almost 50,000 die from it. Screening and surveillance colonoscopies allow CRC to be found earlier, when the disease is easier to cure, and cancers can be prevented if adenomas are removed before they become malignant. 

Colonoscopy is the “gold standard” for detecting cancers and pre-cancerous adenomas in the colon. However, extensive research has shown that even when performed carefully by experienced physicians, standard colonoscopy misses approximately 24% of adenomas of all sizes. 2-4 Even more importantly, standard colonoscopy misses 12% of large adenomas – measuring at least 1 cm in diameter – which are the ones most likely to progress to colon cancer. 5-7

A number of factors have been shown to affect adenoma detection rates, including adequacy of bowel preparation and the amount of time spent examining the lining of the colon. However, approximately 2/3 of adenomas that are missed are located behind the numerous folds in the colon, where they are hidden from the forward view of the colonoscope. 5 Adenomas and other abnormalities in those “blind spots” behind folds are easily missed with a standard colonoscope.

In fact, 7-8% of all cases of CRC are “interval cancers” – found within 2-3 years after the patient has had a “normal” colonoscopy. 8 Previous research had shown that patients examined by endoscopists who have higher adenoma detection rates (ADR) have a lower likelihood of developing an interval cancer. More recently, a landmark study in the New England Journal of Medicine reported that for each 1% increase in an endoscopist's ADR, there is a 3% decrease in the risk of interval cancer and a 5% decrease in the risk for fatal interval cancer. 9

About Avantis Medical Systems and the Third Eye Panoramic Device

Avantis Medical Systems is focused on delivering cost-effective solutions for improved detection and prevention of cancers of the gastrointestinal tract. The company has an extensive portfolio of patents covering innovative devices based on the convergent technologies of micro-chips and enhanced video processing systems.

The Third Eye Panoramic device utilizes ground-breaking technology that was developed for the company’s first device, the Third Eye Retroscope, which was shown in clinical studies to help physicians find up to 23-25% more pre-cancerous adenomas than a standard colonoscope alone. 7

The Third Eye Panoramic device features two video cameras that are directed laterally. Combining their images with the one from the colonoscope’s forward-viewing camera creates an ultra-wide-angle panoramic view.  The Third Eye Panoramic device is designed to be used along with any standard adult or pediatric size colonoscope, so it avoids any substantial capital expense and it allows physicians to continue using the high-quality technologies in which their facilities have already invested, generally including colonoscopes with high-resolution or even high-definition video cameras.

__________________________

1. Rubin M, Lurie L, Bose K, Kim S. Expanding the view of a standard colonoscope with the Third Eye Panoramic cap. World J Gastroenterol 2015;21:10683-7.

2. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-8.

3. Van Rijn JC, Reitsma JB, Dekker E, et al. Polyp Miss Rate Determined by Tandem Colonoscopy: A Systemic Review. Am J Gastroenterol 2006;101:343-50.

4. Heresbach D, Barrioz T, Ponchon T, et al. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. Endoscopy 2008;40:284-90.

5. Pickhardt PJ, Nugent PA, Mysliwiec PA, et al. Location of adenomas missed by optical colonoscopy. Annals of Internal Medicine 2004;141:352-60.

6. Hewett DG, Rex DK. Miss rate of right-sided colon examination during colonoscopy defined by retroflexion: an observational study. Gastrointest Endosc 2011;74:246-52.

7. Siersema PD, Rastogi A, DeMarco DC, et al. Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup. World J Gastroenterol 2012;18:3400-8.

8. Cooper GS, Xu F, Barnholtz-Sloan JS, et al. Prevalence and Predictors of Interval Colorectal Cancers in Medicare Beneficiaries. Cancer 2012;118:3044-52.

9. Corley DA, Jensen CD, Mark AR, et al. Adenoma Detection Rate and Risk of Colorectal Cancer and Death. N Eng J Med 2014;370:1298-306.

Lazar Partners for Avantis Medical Systems, Inc. Chantal Beaudry (646) 871-8480 / (917) 494-0227 cbeaudry@lazarpartners.com Avantis Medical Systems, Inc. Anthony DiTonno (408) 636-7260 aditonno@avantismedical.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 89

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 52

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 30

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 110

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 102

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 49

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 121

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
Limina’s Amberflo Deal Makes AI Usage Visible at Scale

Updated Category News Views 26

Enterprise AI has created a billing fog, and Limina just bought itself a flashlight. Its merger with Amberflo, completed on October 30 and announced November 19, brings metering, cost attribution, and billing technology fully inside Limina’s data-governance platform. No price was disclosed, which is irritating but ordinary for a transaction involving companies that do...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 112

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading

Top 5 Most Recently Viewed Articles

Coveo Earns Recognition as Leader in Generative AI Solutions

Updated Category News Views 244

Coveo Achieves AWS Generative AI Competency Coveo, a frontrunner in the field of AI-Relevance, is thrilled to announce its esteemed recognition for achieving the Amazon Web Services (AWS) Generative AI Competency. This designation not only highlights Coveo's exceptional capabilities but also emphasizes its role in helping businesses harness the power of AI to optimize...

Continue Reading
Legal Inquiry Regarding MediaAlpha, Inc. (MAX) Securities Issues

Updated Category News Views 151

Understanding the Securities Investigation of MediaAlpha, Inc. Investors are currently facing a troubling time as MediaAlpha, Inc. (MAX) finds itself under scrutiny. This investigation, brought forth by a prominent law firm, focuses on potential violations of federal securities laws. The significant implication of these allegations has led many investors to seek clarity...

Continue Reading
Rapid Growth in Data Center Liquid Cooling Market Forecasted

Updated Category News Views 159

Overview of the Data Center Liquid Cooling Market The Data Center Liquid Cooling Market has become a crucial focus in modern technology, with its market size projected to rise from USD 2.99 billion to USD 17.28 billion. This significant growth, a Compound Annual Growth Rate (CAGR) of 21.54% from 2024 to 2032, indicates a transitioning landscape in data management...

Continue Reading
Eupraxia Pharmaceuticals Shares Exciting Updates on EoE Trial

Updated Category News Views 327

Eupraxia Pharmaceuticals' Latest Trial Results for EP-104GI Eupraxia Pharmaceuticals Inc. (TSX: EPRX) has reported exciting news regarding its ongoing clinical trial for the treatment of eosinophilic esophagitis (EoE) with EP-104GI. This treatment aims to alleviate symptoms and improve the quality of life for patients suffering from this challenging condition. Highlights...

Continue Reading
Innovative Robotics Solutions Set to Transform Warehousing

Updated Category News Views 253

Revolutionizing Warehouse Operations with Robotics Autonomous forklifts are taking a leap forward by adapting into existing warehouse environments, promising a quick return on investment. The robotics innovator, Riibotics, is poised to present its innovative solutions at RoboBusiness 2025. This event is taking place at the Santa Clara Convention Center, where Riibotics...

Continue Reading